Patient-Clinician-Regulator Alignment: A New Framework
- MILAN — Measurable residual disease (MRD), formerly known as minimal residual disease, is rapidly changing how hematologic malignancies are managed.
- Jesus San Miguel Izquierdo,MD,PhD,from the University of Navarra,emphasized the technological advancements enabling the detection of a single tumor cell among a million.
- At the European Hematology Association (EHA) 2025 Annual Meeting, patient advocates, clinicians, and regulators discussed MRD's expanding role.
Measurable residual disease (MRD) is transforming the landscape of hematologic malignancy treatment. This article delves into MRD’s critical role, influencing prognosis adn treatment strategies. Patient advocates, clinicians, and regulators are actively discussing the impact of MRD on treatment decisions and the emotional weight of MRD results. Explore how MRD impacts ALL, AML, and MM patients and affects eligibility for novel therapies.News Directory 3 provides insights into how MRD is shaping clinical trial designs and prompting personalized treatment approaches, regulatory considerations, and the need for global standardization. Discover what’s next in the evolution of patient-centered medicine and quality of life.
MRD’s Expanding Role in Hematologic Malignancies: A Hopeful Yet anxious Tool
Updated June 15, 2025
MILAN — Measurable residual disease (MRD), formerly known as minimal residual disease, is rapidly changing how hematologic malignancies are managed. Once a research tool, MRD now considerably impacts clinical and regulatory decisions in conditions like acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). It informs prognosis, therapeutic response, and access to innovative treatments.
Jesus San Miguel Izquierdo,MD,PhD,from the University of Navarra,emphasized the technological advancements enabling the detection of a single tumor cell among a million. He received the 2025 EHA Lifetime Achievement Award for his work in MM.
At the European Hematology Association (EHA) 2025 Annual Meeting, patient advocates, clinicians, and regulators discussed MRD’s expanding role. While its utility in indicating treatment response is recognized, standardization, regulatory implications, and patient experience remain debated.
The Patient Voice: Hope and Anxiety
Anne-Pierre Pickaert, an ALL survivor and patient advocate, described MRD as a “needle in a haystack,” highlighting the emotional burden of uncertainty, even when cancer cells are undetectable. The shift from “minimal” to ”measurable” can also cause anxiety, despite its clinical precision.
MRD’s implications vary across diseases. In ALL and AML, MRD status affects eligibility for transplants, trials, and novel therapies. Patients with chronic lymphocytic leukemia or lymphoma may be less familiar with MRD, reflecting its inconsistent use. Pickaert coined the term “MRD-xiety,” akin to “scanxiety,” emphasizing the emotional weight of MRD results in determining treatment.
Clinician Perspective: A Therapeutic Shift
Nicola Gökbuget, MD, from the University Cancer Center in Frankfurt, highlighted MRD’s transformative impact on clinical strategy. In ALL, persistent or re-emerging MRD can prompt therapeutic changes, influencing clinical trial designs and enabling personalized approaches. However,standardized definitions for response categories and harmonized testing are crucial.
The Regulatory View: Surrogacy and Utility
Pierre Démolis, MD, PhD, from the European Medicines Agency, discussed the regulatory perspective on MRD. While a powerful indicator, MRD isn’t yet a validated surrogate endpoint, requiring consistent correlation with overall survival. Démolis advocates for MRD as a “response trigger” in adaptive designs and early treatment assessments, clarifying the distinction between activity (e.g., MRD negativity) and efficacy (e.g., overall survival).
divergence in Attitudes
Anna Smit,a PhD candidate at Erasmus MC Cancer Institute,presented survey findings on MRD in MM trials. Most healthcare professionals and regulators supported MRD negativity as a primary endpoint, emphasizing the need for global standardization. The FDA’s Oncologic Drugs Advisory Committee supported MRD-negative complete response as an endpoint for accelerated approval in MM, but Europe has not yet agreed.
Patient-Centered medicine
Quality of life (QoL) is crucial in managing hematologic malignancies. Pickaert emphasized that patients want survival, but not at any cost. Démolis echoed this, stating that prolonging life at the expense of QoL is not meaningful. Integrating QoL into MRD-based strategies ensures treatments extend both life and well-being.
San Miguel Izquierdo linked early intervention, guided by MRD, to better QoL, noting that undertreatment poses a greater risk than overtreatment.
What’s next
The field continues to evolve, with ongoing efforts to standardize MRD testing and integrate patient-centered outcomes into treatment decisions, aiming for a balance between survival and quality of life.